The DNA of the U.S. Regulatory System: Are We Getting It Right for Synthetic Biology?
The pathway to market for new products utilizing synthetic biology can be difficult to navigate, posing a challenge for companies in their efforts to commercialize new ideas, while the novelty posed by some of these products can make it difficult for regulatory agencies to evaluate risks, according to a new report from the Synthetic Biology …
The DNA of the U.S. Regulatory System: Are We Getting It Right for Synthetic Biology? Read More »